Cortexin
Also known as: Bovine brain peptide preparation
A standardised low-molecular-weight peptide preparation derived from bovine cerebral cortex, used in Russian clinical practice for cognitive impairment, post-stroke recovery, and traumatic brain injury research — the closest single sister to Cerebrolysin.
- Category
- Neuroprotection
- Half-life
- Multi-component preparation with varied pharmacokinetics
Section 1
Overview
Cortexin is a complex peptide preparation produced by acetic-acid extraction and standardised processing of bovine cerebral cortex tissue. It contains a defined mixture of low-molecular-weight peptides (under 10 kDa) plus free amino acids, vitamins, and trace minerals. Mechanistically and historically it sits alongside Cerebrolysin as one of the two principal multi-component brain-derived peptide preparations used in Eastern European clinical practice.
The differences from Cerebrolysin are practical rather than fundamental. Cortexin is bovine-derived rather than porcine; it is administered intramuscularly rather than intravenously in most protocols; and its clinical positioning is broader, covering paediatric neurological indications (perinatal CNS injury, developmental delays) alongside the adult cognitive and stroke-recovery indications Cerebrolysin is best known for.
Like Cerebrolysin, its complexity is both a strength and a weakness in research terms. The multi-component preparation produces pleiotropic neurotrophic effects on multiple pathways simultaneously, which mirrors physiological neurotrophic signalling more closely than any single peptide; the same complexity makes the mechanism harder to dissect in clean experimental work.
Section 2
Discovery & History
- Developed in the Soviet Union in the late 1980s and registered as a medicinal product in Russia in 1999.
- Standard prescription medication in Russia and several CIS countries for a range of cognitive, cerebrovascular, and developmental indications.
- Subject to a substantial Russian-language clinical-trial body in stroke recovery, vascular dementia, traumatic brain injury, and paediatric neurology.
- Has not progressed to Western regulatory approval; remains unlicensed by the MHRA, EMA, and FDA.
Section 3
Mechanism of Action
- 1Multi-component neurotrophic factor mimicry — the preparation contains fragments that reproduce aspects of BDNF, NGF, GDNF, and CNTF signalling without being any one of those molecules.
- 2Modulation of GABAergic and glutamatergic balance in cortical neurons, contributing to its reported anticonvulsant and neuroprotective properties.
- 3Antioxidant effects via upregulation of endogenous antioxidant enzyme expression and direct radical scavenging.
- 4Anti-apoptotic effects in models of ischaemic and traumatic neuronal injury.
- 5Modulation of microglial activation and reduction of neuroinflammatory mediator release in CNS injury models.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Cognitive improvement in cerebrovascular disease and post-stroke populations in Russian clinical trials.
- 2Reported neuroprotective effects in traumatic-brain-injury research, including paediatric indications.
- 3Anticonvulsant adjunct effects studied in epilepsy research.
- 4Broad clinical use profile across paediatric and adult indications, providing extensive real-world experience.
- 5Long track record of post-marketing safety data in Russian and CIS clinical practice.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intramuscular injection (clinical use in approving jurisdictions) | Typical clinical doses 5–10 mg per injection | Daily during a treatment cycle | Cycles of 10 days, sometimes repeated after intervals |
Note: Not approved or prescribed in the UK; this information is for educational reference only.
Section 6
Administration Routes
- Intramuscular injection — the standard clinical route.
- Oral administration is not used; the bioactive peptides are degraded by gastrointestinal proteases.
- Intranasal administration has been explored in research but is not the standard clinical route.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in Russian clinical use
- · Mild injection-site reactions reported in some patients
- · Occasional hypersensitivity reactions — local rash or urticaria
Rare / theoretical
- · Anaphylactic reactions to the bovine-derived preparation, as with any animal-protein biologic
- · Theoretical considerations around prion or other transmissible-disease risk in animal-derived biologics, managed by purification and screening in approved manufacture
Contraindications
- · Not licensed in the UK
- · Known hypersensitivity to bovine-derived proteins
- · Pregnancy and lactation (per labelling in approving jurisdictions)
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the UK. Used clinically in the Russian Federation and several CIS countries.
European Union
Not approved by the EMA. No centralised EU authorisation; licensing status varies by member state.
Section 9
Clinical Studies Summary
Cortexin in post-stroke cognitive recovery
Russian multicentre study reporting accelerated recovery of cognitive function in patients receiving adjunct Cortexin during the rehabilitation phase versus standard care alone.
Cortexin in paediatric perinatal CNS injury
Russian clinical research in neonates with hypoxic-ischaemic encephalopathy reporting improved neurodevelopmental outcomes at follow-up in the treated group.
Comparative study of Cortexin and Cerebrolysin in vascular dementia
Russian comparative trial reporting broadly similar cognitive outcomes between the two preparations on standardised cognitive batteries, with differences in tolerability profile.
Section 10
Frequently Asked Questions
Section 11
Sourcing for Laboratory Research
Sourcing Cortexin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Cortexin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.